DuPont/Nova

03 Apr 1989
News

Executive Summary

DuPont Medical Products signs five-year agreement with receptor R&D firm Nova Pharmaceutical covering development and marketing of products for the molecular screening of chemical compounds for biological activity. Using its NovaScreen technology, Nova will develop and test products for DuPont, which will receive manufacturing and marketing rights. The first products will be kits for performing receptor binding assays. Nova also has drug screening pacts with Sterling and NIH as well as with several Japanese firms.

Existing Subscriber? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS015338

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS015338

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

DuPont/Nova

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

DuPont/Nova

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert